Pacritinib (formerly SB1518) is an oral small molecule that selectively and potently inhibits JAK2, showing promising in vitro activity in JAK2-dependent DLBCL cell lines independent of JAK2 mutational status [273]. The gene discussed is JAK2; the disease is diffuse large B-cell lymphoma.